Bosentan 125mg Tablets

Bosentan 125mg Tablets are a highly effective therapeutic agent belonging to the class of medications known as endothelin receptor antagonists (ERAs). Specifically designed for the management of Pulmonary Arterial Hypertension (PAH), this medication functions as a dual antagonist, blocking both endothelin A (ETA) and endothelin B (ETB) receptors.

In patients with PAH, neurohormones called endothelins are often elevated, leading to the constriction (narrowing) of blood vessels in the lungs and the proliferation of smooth muscle cells. By competitively binding to these receptors, Bosentan 125mg Tablets prevent the potent vasoconstrictive effects of endothelin-1. This action results in significant vasodilation (widening) of the pulmonary arteries, which reduces pulmonary vascular resistance. Consequently, the workload on the right side of the heart is decreased, leading to improved cardiac output and alleviation of the debilitating symptoms associated with the disease.

Indications / Uses of Bosentan 125mg Tablets

Bosentan 125mg Tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO Class II, III, and IV symptoms. It is prescribed to improve exercise ability and decrease the rate of clinical worsening. Common indications include:

• Idiopathic or Heritable PAH: Used for patients with PAH that has no known cause or is inherited, helping to manage high blood pressure in the lungs and improve physical endurance.
• PAH Associated with Connective Tissue Diseases: It is particularly effective for patients with PAH related to scleroderma (systemic sclerosis) or lupus, conditions where pulmonary vascular complications are common.
• PAH Associated with Congenital Heart Defects: Prescribed for patients with Eisenmenger physiology (congenital heart shunts) to reduce pulmonary vascular resistance and improve oxygenation.
• Reduction of Digital Ulcers: In patients with systemic sclerosis and active digital ulcer disease, Bosentan 125mg Tablets are indicated to reduce the number of new digital ulcers appearing.

Key Features

• Dual Receptor Antagonism: Unlike selective ERAs, Bosentan 125mg Tablets block both ETA and ETB receptors, offering comprehensive inhibition of the endothelin pathway.
• Oral Formulation: The 125mg tablet is designed for convenient oral administration, typically taken twice daily (morning and evening) with or without food.
• Hemodynamic Improvement: Clinical studies have demonstrated its ability to significantly lower pulmonary artery pressure and increase cardiac index, leading to better long-term outcomes.
• Improved Exercise Capacity: Patients treated with this medication often show a measurable increase in the distance they can walk in six minutes (6MWD), a key marker of functional status in PAH.
• Maintenance Dosing: The 125mg strength is the standard maintenance dose for adults, reached after an initial titration period of 4 weeks at a lower dose.

Storage for Bosentan 125mg Tablets

To ensure the stability and safety of Bosentan 125mg Tablets, it is important to store them correctly. Keep the medication at controlled room temperature, ideally between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Store the tablets in their original container to protect them from moisture and light. Do not transfer them to a pill organizer unless it protects against humidity. Keep the container tightly closed and store it in a safe place, out of the reach and sight of children and pets, as accidental ingestion can be harmful.

Important Note on Bosentan 125mg Tablets

Bosentan 125mg Tablets carry a Boxed Warning for two major risks: hepatotoxicity (liver injury) and embryo-fetal toxicity. Because Bosentan can cause elevations in liver aminotransferases (ALT/AST) and, in rare cases, liver failure, monthly monitoring of liver function tests is mandatory for all patients. Due to these risks, the drug is available only through a restricted distribution program known as the Bosentan REMS.

This medication is strictly contraindicated in pregnancy as it is teratogenic and can cause major birth defects. Female patients of reproductive potential must have a negative pregnancy test before starting treatment, monthly during treatment, and for one month after stopping. They must also use reliable forms of contraception. Hormonal contraceptives (pills, patches, implants) may not be effective when taken with Bosentan 125mg Tablets due to drug interactions, so non-hormonal barrier methods are required.

Other common side effects include headache, nasopharyngitis, flushing, and edema (swelling of the legs and ankles). Bosentan 125mg Tablets can also decrease hemoglobin levels, so blood counts should be monitored regularly. It is a significant inducer of CYP2C9 and CYP3A4 enzymes, leading to numerous potential drug interactions (e.g., with glyburide, cyclosporine, warfarin), which must be managed by a healthcare professional.